» Articles » PMID: 12037221

Antibiotic Resistant Tuberculosis in the United Kingdom: 1993-1999

Overview
Journal Thorax
Date 2002 May 31
PMID 12037221
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The re-emergence of tuberculosis as a global health problem over the past two decades, accompanied by an increase in tuberculosis drug resistance, prompted the development of a comprehensive national surveillance system for tuberculosis drug resistance in 1993.

Methods: The UK Mycobacterial Resistance Network (Mycobnet), which includes all mycobacterial reference and regional laboratories in the UK, collects a minimum dataset on all individuals from whom an initial isolate of Mycobacterium tuberculosis complex has been isolated and submitted by source hospital laboratories. Data sought include susceptibility to first line antibiotics, demographic, geographical, and risk factor information.

Results: There were 25 217 reports of initial isolates of M tuberculosis complex in the UK between 1993 and 1999. All were tested for sensitivity to isoniazid, rifampicin, and ethambutol and 12 692 of the isolates were also tested for sensitivity to pyrazinamide and streptomycin. A total of 1523 (6.1%) isolates were resistant to one or more drugs, 1397 isolates (5.6%) were resistant to isoniazid with or without resistance to other drugs, and 299 (1.2%) were multidrug resistant. Although the numbers of drug resistant isolates increased over the period, the proportions remained little changed. Certain groups of people were at a higher risk of acquiring drug resistant tuberculosis including younger men, residents of London, foreign born subjects, patients with a previous history of tuberculosis and those infected with HIV.

Conclusion: Although the proportion of drug resistant tuberculosis cases appears to be stable in the UK at present, more than one in 20 patients has drug resistant disease at diagnosis and more than one in 100 has multidrug resistant disease. Tuberculosis control measures should be strengthened to minimise the emergence of drug resistance through rapid diagnosis, rapid identification of drug resistance, supervised treatment, and maintenance of comprehensive surveillance.

Citing Articles

Risk factors for treatment failure in multidrug resistant tuberculosis in Tunisia: An analytic study.

Tritar F, Ben Saad S, Ferchichi M, Ben Mansour A, Slim A, Neffati O Tunis Med. 2024; 102(1):44-48.

PMID: 38545729 PMC: 11261501. DOI: 10.62438/tunismed.v102i1.4521.


The impact of diabetes mellitus on the emergence of multi-drug resistant tuberculosis and treatment failure in TB-diabetes comorbid patients: a systematic review and meta-analysis.

Ur Rehman A, Khattak M, Mushtaq U, Latif M, Ahmad I, Rasool M Front Public Health. 2023; 11:1244450.

PMID: 38074769 PMC: 10704033. DOI: 10.3389/fpubh.2023.1244450.


Global prevalence of drug-resistant tuberculosis: a systematic review and meta-analysis.

Salari N, Kanjoori A, Hosseinian-Far A, Hasheminezhad R, Mansouri K, Mohammadi M Infect Dis Poverty. 2023; 12(1):57.

PMID: 37231463 PMC: 10210422. DOI: 10.1186/s40249-023-01107-x.


Drug-Resistant Tuberculosis Among Children: A Systematic Review and Meta-Analysis.

Song W, Li Y, Liu Y, Liu Y, Yu C, Liu J Front Public Health. 2021; 9:721817.

PMID: 34490197 PMC: 8416474. DOI: 10.3389/fpubh.2021.721817.


Analysis of novel fractional COVID-19 model with real-life data application.

Inc M, Acay B, Berhe H, Yusuf A, Khan A, Yao S Results Phys. 2021; 23:103968.

PMID: 33654656 PMC: 7906878. DOI: 10.1016/j.rinp.2021.103968.


References
1.
Brown P . Drug resistant tuberculosis can be controlled, says WHO. BMJ. 2000; 320(7238):821. PMC: 1127184. View

2.
Breathnach A, de Ruiter A, Holdsworth G, Bateman N, OSULLIVAN D, Rees P . An outbreak of multi-drug-resistant tuberculosis in a London teaching hospital. J Hosp Infect. 1998; 39(2):111-7. DOI: 10.1016/s0195-6701(98)90324-3. View

3.
Drobniewski F, Watterson S, Wilson S, Harris G . A clinical, microbiological and economic analysis of a national service for the rapid molecular diagnosis of tuberculosis and rifampicin resistance in Mycobacterium tuberculosis. J Med Microbiol. 2000; 49(3):271-278. DOI: 10.1099/0022-1317-49-3-271. View

4.
Frieden T, Sterling T, Pablos-Mendez A, Kilburn J, Cauthen G, DOOLEY S . The emergence of drug-resistant tuberculosis in New York City. N Engl J Med. 1993; 328(8):521-6. DOI: 10.1056/NEJM199302253280801. View

5.
Ormerod L, Charlett A, Gilham C, Darbyshire J, Watson J . Geographical distribution of tuberculosis notifications in national surveys of England and Wales in 1988 and 1993: report of the Public Health Laboratory Service/British Thoracic Society/Department of Health Collaborative Group. Thorax. 1998; 53(3):176-81. PMC: 1745172. DOI: 10.1136/thx.53.3.176. View